CANCER AND LEUKEMIA GROUP B

描述（改编自申请人的摘要）： 芝加哥对实验室和临床癌症都有重大承诺 1930年以来的研究。 作为该研究临床转化的一部分， 芝加哥大学及其癌症研究中心加入了癌症研究小组， 和白血病组B（CALGB）在1985年，并随后强烈 在科学和临床上支持了CALGB。 很多协议， 委员会和项目由芝加哥的教师领导。 过去五 芝加哥大学在2004年增加了184例患者的应计费用， 点到294病人点，在1996年，27%的主要成员的 患者增加为非裔美国人。 这些成就是由 纪律活动的主要成员，也支持七个 专门的附属机构在北方伊利诺伊州，密歇根州和 印第安纳州。 芝加哥正在增加三个新的分支机构， 明年，并仍然非常参与培训和质量控制， 所有附属机构。 本申请的目标是：（1） 将患者增加至300-350例患者/年;（2）领导和 协助CALGB在疾病相关委员会中的科学活动， 呼吸系统（Vokes和Olak博士）、前列腺（Vogelzang、Steinberg和 Vijaykumar），乳房（弗莱明博士），白血病（拉森博士）和GI（博士。 （3）领导、协助和参与CALGB委员会， 心理/肿瘤学（Marcy List，博士），Pharmacology and experimental 治疗学（Ratain博士），移植（威廉姆斯博士），遗传学（Dr. Olopade），艾滋病相关恶性肿瘤（Liebowitz博士），外科肿瘤学（Dr. Michelassi）和病理学（Vardiman博士）;（4）鼓励芝加哥教师 担任未来议定书的议定书主席;（5）积极协助和 参加审计、少数民族问题、肿瘤学等CALGB委员会 护理、癌症控制和放射治疗。 芝加哥大学 建议通过以下方法实现这些目标：（1） 在新能源的帮助下，增加主要成员的收益 结肠直肠癌、乳腺癌、外科、白血病和前列腺癌方面的医生， 为第一、第二和第三阶段议定书提出新的想法; ⑵维持 附属医院的高应计费用， 增加新的合格的分支机构;（3）保持强有力的领导作用 Vogelzang，Vokes，Larson，Schilsky，Ratain，威廉姆斯，Olopade，List博士的 Vardiman和Michelassi在CALGB内;（4）招募新的年轻人 研究人员对CALGB领导作用（曼尼博士，莱博维茨和 特别是那些具有特定实验室专业知识的人， 与临床治疗或结果相关;（5）提供 志愿者为众多CALGB行政委员会。 大学 芝加哥及其附属机构仍然坚定地致力于为所有成员提供服务， 他们各自的社区，特别是满足妇女的需要， 少数群体

DESCRIPTION (adapted from the applicant's abstract): The University of Chicago has had a major commitment to both laboratory and clinical cancer research since 1930. As part of the clinical translation of that research, the University of Chicago and its Cancer Research Center joined the Cancer and Leukemia Group B (CALGB) in 1985, and has subsequently strongly supported the CALGB both scientifically and clinically. Numerous protocols, committees, and programs are lead by Chicago faculty. Over the past five years the University of Chicago has increased its accrual from 184 patient points to 294 patient points, and in 1996 27 percent of the main member's patient accrual was African American. These accomplishments occurred by disciplined activity at the main member and also by supporting seven dedicated affiliated institutions in northern Illinois, Michigan and Indiana. Chicago is in the process of adding three new affiliates in the next year and remains very involved with the training and quality control of all its affiliate institutions. The goals of this application are: (1) increase the patient accrual to 300-350 patients/year; (2) to lead and assist CALGB scientific activities in the disease-related committees of respiratory (Drs. Vokes and Olak), prostate (Drs. Vogelzang, Steinberg and Vijaykumar), breast (Dr. Fleming), leukemia (Dr. Larson) and GI (Dr. Mani); (3) to lead and assist and participate in the CALGB committees such as psycho/oncology (Marcy List, Ph.D.), pharmacology and experimental therapeutics (Dr. Ratain), transplantation (Dr. Williams), genetics (Dr. Olopade), AIDS related malignancies (Dr. Liebowitz), surgical oncology (Dr. Michelassi) and pathology (Dr. Vardiman); (4) to encourage Chicago faculty to be protocol chairs for future protocols; and (5) to actively assist and participate in the CALGB committees of audit, minority issues, oncology nursing, cancer control, and radiotherapy. The University of Chicago proposes to accomplish these goals by the following methods: (1) to increase accrual from the main member with the assistance of new energetic physicians in colorectal, breast, surgery, leukemia and prostate cancer and by generating new ideas for phase I, II and III protocols; (2) to maintain the high accrual from the affiliate hospitals and increasing accrual by adding new qualified affiliates; (3) to maintain the strong leadership roles of Drs. Vogelzang, Vokes, Larson, Schilsky, Ratain, Williams, Olopade, List, Vardiman and Michelassi within the CALGB; (4) to recruit new young investigators to CALGB leadership roles (Drs. Manni, Leibowitz and Daugherty); especially those with a specific laboratory expertise which can be correlated with clinical treatment or outcome; and (5) to provide volunteers for numerous CALGB administrative committees. The University of Chicago and its affiliates remain firmly committed to serving all members of their respective communities, especially serving the needs of women and minorities.